Blar i Department of Clinical Science på emneord "p53"

Viser treff 1-2 av 2

    • Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo 

      Knappskog, Stian; Berge, Elisabet Ognedal; Chrisanthar, Ranjan; Geisler, Stephanie; Staalesen, Vidar; Leirvaag, Beryl; Yndestad, Synnøve; de Faveri, Elise Norheim; Karlsen, Bård Ove; Wedge, David C.; Akslen, Lars A.; Lilleng, Peer Kåre; Løkkevik, Erik; Lundgren, Steinar; Østenstad, Bjørn; Risberg, Terje; Mjaaland, Ingvil; Aas, Turid; Lønning, Per Eystein (Peer reviewed; Journal article, 2015-10)
      Chemoresistance is the main obstacle to cancer cure. Contrasting studies focusing on single gene mutations, we hypothesize chemoresistance to be due to inactivation of key pathways affecting cellular mechanisms such as ...

    • Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia 

      Haaland, Ingvild; Opsahl, Jill Anette; Berven, Frode S.; Reikvam, Håkon; Fredly, Hanne Kristin; Haugse, Ragnhild; Thiede, Bernd; McCormack, Emmet; Lain, Sonia; Bruserud, Øystein; Gjertsen, Bjørn Tore (Peer reviewed; Journal article, 2014-05-21)
      Background: The small-molecule MDM2 antagonist nutlin-3 has proved to be an effective p53 activating therapeutic compound in several preclinical cancer models, including acute myeloid leukemia (AML). We and others have ...